$1.32
+0.02 (+1.54%)
Open$1.31
Previous Close$1.30
Day High$1.34
Day Low$1.29
52W High$4.07
52W Low$0.81
Volume—
Avg Volume117.5K
Market Cap22.51M
P/E Ratio—
EPS$-1.23
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,132.6% upside
Current
$1.32
$1.32
Target
$16.27
$16.27
$12.16
$16.27 avg
$21.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.81M | 7.34M | 3.86M |
| Net Income | -20,851,101 | -10,752,917 | -155,305 |
| Profit Margin | -162.8% | -154.7% | -4.0% |
| EBITDA | -21,603,136 | -11,759,671 | -205,551 |
| Free Cash Flow | — | — | -168,121 |
| Rev Growth | +74.5% | +74.5% | +19.6% |
| Debt/Equity | — | — | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |